Drug Shortage Report for ZOMETA CONCENTRATE
| Report ID | 125066 |
| Drug Identification Number | 02248296 |
| Brand name | ZOMETA CONCENTRATE |
| Common or Proper name | ZOMETA CONCENTRATE VIAL 4MG/5ML |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | ZOLEDRONIC ACID |
| Strength(s) | 4MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 5ML |
| ATC code | M05BA |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2020-10-19 |
| Actual start date | |
| Estimated end date | Unknown |
| Actual end date | 2020-10-08 |
| Shortage status | Avoided shortage |
| Updated date | 2020-10-19 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2020-10-19 | French | Compare |
| v4 | 2020-10-19 | English | Compare |
| v3 | 2020-09-25 | French | Compare |
| v2 | 2020-09-25 | English | Compare |
| v1 | 2020-09-25 | English | Compare |
Showing 1 to 5 of 5